“It is vital to identify patients who are at a high risk for ACS after TAVR for potential treatment beforehand,” according a new analysis published in the American Journal of Cardiology.

Clopidogrel is especially effective at limiting major adverse cardiovascular events among PCI patients with diabetes, researchers found. 

The company is still riding the momentum of its technology being included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines.

This latest recall is due to a heightened risk that the devices will stop working with no warning. There have been 42 customer complaints reported so far. 

The devices have been hit with multiple recalls in recent months. Those issues are now impacting sales outside of the United States as well.

Patients hospitalized for severe infectious diseases are at heightened risk of major cardiovascular-disease events within a month of admission date. 

Reviewing data from more than 800,000 patients, researchers also emphasized that patients vaccinated against COVID-19 are less likely to experience long-lasting symptoms.

The recall includes approximately 2,300 devices distributed to customers prior to July 24, 2017. There have been 44 complaints about this issue so far.